Skip to main content

GLP-1 RAs Reduce Risk for Clinically Important Kidney, CVD Outcomes

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 6, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Dec. 6, 2024 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascular disease outcomes in individuals with type 2 diabetes, according to research published online Nov. 25 in The Lancet Diabetes & Endocrinology.

Sunil V. Badve, Ph.D., from the University of New South Wales in Sydney, and colleagues conducted a meta-analysis of randomized controlled trials that compared a GLP-1 RA to placebo among participants with type 2 diabetes. Post hoc, the SELECT trial, which enrolled participants with cardiovascular disease and a body mass index of 27 kg/m2 or greater without diabetes, was included. The meta-analysis included 11 trials with 85,373 participants (67,769 with type 2 diabetes).

The researchers found that GLP-1 RAs reduced the composite kidney outcome, kidney failure, major adverse cardiovascular events (MACE), and all-cause death compared with placebo (hazard ratios, 0.82, 0.84, 0.87, and 0.88, respectively) in participants with type 2 diabetes. On inclusion of the SELECT trial, the effect on the composite kidney outcome, kidney failure, MACE, and all-cause death was similar (hazard ratios, 0.81, 0.84, 0.86, and 0.87, respectively), with no evidence of heterogeneity between the trials. The GLP-1 RA and placebo groups had no differences in the risk for serious adverse events, including acute pancreatitis and severe hypoglycemia.

"Taken together, these results and the breadth of the benefits observed support an important role for GLP-1 receptor agonists as kidney-protective and heart-protective medications that could play an important role in addressing the global burden of noncommunicable diseases," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted December 2024

Read this next

Adherence to Healthy Diet Improves Cardiometabolic Risk, Even Without Weight Loss

WEDNESDAY, June 11, 2025 -- A healthy diet improves cardiometabolic risk factors, even if not associated with weight loss (WL), according to a study published online June 5...

Standard-Criteria Kidney Transplant Offers Clear Survival Benefit Over Continued Dialysis

TUESDAY, June 10, 2025 -- Transplantation with standard-criteria kidney offers a clear survival benefit, but this decreases with age and for those with a history of cardiovascular...

Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM

MONDAY, June 9, 2025 -- For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.